Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.75 +0.94 (+2.05%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,116,065
Open 45.99
Bid (Size) 46.35 (2)
Ask (Size) 46.50 (2)
Prev. Close 45.81
Today's Range 45.80 - 46.80
52wk Range 39.35 - 63.30
Shares Outstanding 2,222,113,553
Dividend Yield 5.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb
Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock. 
Via Benzinga
Topics Government
Exposures Political
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Exposures Political

Performance

YTD
-17.7%
-17.7%
1 Month
-5.3%
-5.3%
3 Month
-13.3%
-13.3%
6 Month
-16.8%
-16.8%
1 Year
+6.0%
+6.0%

More News

Read More
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
Via Chartmill
What's going on in today's session: S&P500 movers
Via Chartmill
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
Exposures Interest Rates Political
Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
Via Benzinga
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
Via Stocktwits
Topics Government
Exposures Political
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Via Benzinga
Exposures Product Safety
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements
Via StockStory
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
3 Healthcare Stocks in Hot Water
Via StockStory
Topics Economy Stocks
Exposures COVID-19 Supply Chain US Equities
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
Via Benzinga
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
Via Chartmill
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Via Benzinga
Exposures Product Safety
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
From Bristol Myers Squibb
Via Business Wire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 46.75
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 05/16/25 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 103.88B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 104B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback